Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial
Siebert S, Schett G, Raychaudhuri S, Guma M, Chen W, Gao S, Chakravarty S, Lavie F, Rahman P. Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial. Therapeutic Advances In Musculoskeletal Disease 2024, 16: 1759720x241283536. PMID: 39493888, PMCID: PMC11528637, DOI: 10.1177/1759720x241283536.Peer-Reviewed Original ResearchActive psoriatic arthritisDisease activityPharmacodynamic effectsC1MActive PsADISCOVER-2Psoriatic arthritisIL-6Phase III randomized controlled trialsAmerican College of Rheumatology response criteriaBiomarker levelsBD-2 levelsC1M levelsAssociated with durable improvementsJoint disease activityOverall disease activityEffect of guselkumabSerum biomarker dataM levelsC6M levelsRandomized controlled trialsFollow-up timepointsClinical responseACR50 responseIL-17A